We just covered the Jim Cramer Stock Portfolio: Top 10 Stock Picks. Eli Lilly and Company (NYSE:LLY) ranks #9 (see the Jim Cramer’s top 5 stock picks in 2026 here). Jim Cramer has long been a believer in Eli Lilly and Company (NYSE:LLY). In November, he said on CNBC that the company is likely to hit the $1 trillion market cap milestone amid its weight-loss pill catalyst. LLY is a key part of Jim Cramer stock portfolio for 2026. Eli Lilly and Company (NYSE:LLY) is preparing to launch its new oral obesity ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q4 2025 investor letter. A copy of the letter can be downloaded here. The US stock market delivered modest gains in the quarter with the S&P 500 index (“S&P”) and the Russell 1000 Growth index (“RLG”) returning 2.6% and 1.1%, respectively. The Fund appreciated by 1.4% during the same period. For the full year, the Fund was up 13.3% vs. 17.4% and 18.6% gains, respect ...

Key Takeaways Lilly's Mounjaro and Zepbound generated $36.5B in 2025, over 50% of total revenuesNew drugs and obesity pipeline, including orforglipron, are expected to fuel 2026 growthAbbVie's Skyrizi and Rinvoq drove strong sales, offsetting Humira erosion and supporting outlookEli Lilly (LLY) and AbbVie (ABBV) are leading, well-established U.S. drugmakers with multiple blockbuster therapies, strong R&D pipelines, significant market capitalizations and extensive global reach. Both maintain a solid presence ...

美股频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 来源：环球市场播报 信达生物发布公告，关公司于2026年2月8日就与礼来制药签署战略合作协议以推动肿瘤学及免疫学领域 新药研发所作出的公告。公司已获联邦贸易委员会提前批准，至此，礼来制药与公司之间战略合作协议 生效的所有先决条件均已达成。该战略合作协议已于香港时间2026年3月24日生效。 公司注意到，部分媒体报导错误地将该战略合作协议的生效解读为对公司的收购。公司谨此澄清，公司 并未，亦无意进行该等交易。谨此提醒股东及有意投资者，切勿依赖有关集团的市场传闻。有关集团的 任何资讯，应仅以公司的官方公告为准。 ...

Like many growth stocks, drugmaker Eli Lilly (NYSE: LLY) is down sharply year to date. Its 15.6% decline is weighing on the healthcare sector, as research by The Motley Fool shows that Lilly is by far the most valuable U.S. healthcare company. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Below we'll look at why it's under pressure, a ...

Quick Read iShares U.S. Pharmaceuticals ETF (IHE) has 46.8% of its $1.1B portfolio concentrated in Johnson & Johnson (JNJ), up 14% year-to-date on strong DARZALEX sales of $3.90B, and Eli Lilly (LLY), down 15% year-to-date despite Mounjaro hitting $7.41B in Q4 2025 revenue. The fund itself is flat year-to-date, down 0.5%, reflecting opposing performance between its two dominant holdings facing pricing pressure and manufacturing constraints. The Trump administration’s aggressive drug pricing reform thro ...

整理 | GLP1减重宝典内容团队 过去几周，市场盯着诺和诺德看的，几乎都是权力斗争。CEO被撤，董事会大换血，创始家族重新收紧控制权，公司内部的紧张气氛几 乎已经摆到了台面上。外界对这家丹麦巨头的判断，也一度越来越悲观：一边是礼来在减重药市场节节推进，一边是诺和诺德自己的下 一代产品没有如预期那样顺利接棒，管理层又在这个时候发生剧烈动荡，这几乎是一家龙头公司最不愿意同时面对的局面。 但就在这场宫斗最激烈的时候，诺和诺德终于等到了一条真正像样的产品线利好。3月19日，美国 FDA 批准了更高剂量版 Wegovy，也 就是 Wegovy HD，剂量为每周 7.2mg。诺和诺德随后确认，这款产品在关键的 72 周晚期研究中，实现了平均 20.7% 的体重降幅，而现 有 2.4mg 剂量版本的平均降幅为 17.5%。英国和欧盟其实已经在今年更早时候批准了这一更高剂量版本，美国的放行则意味着，诺和诺 德终于在最核心的市场里，把自己的减重效果往礼来的水平又推近了一大步。 点击关注，追踪最新GLP-1资讯 这 20.7% 为什么重要？因为过去两年，礼来几乎就是靠着"效果更强"这一点，一步一步把市场优势做出来的。礼来的 Z ...

Eli Lilly & Company (NYSE:LLY) ranks among the best high profit margin stocks to buy. Following the reveal of an innovative employer access platform for obesity therapies, Morgan Stanley reiterated its Overweight rating and $1,313 price target for Eli Lilly & Company (NYSE:LLY) on March 5. Eli Lilly recently established its Employer Connect platform in the US, which provides flexible benefit designs geared at increasing access to obesity treatments like Zepbound. Pixabay/Public Domain In order to produc ...

2026.03. 24 本文字数：2990，阅读时长大约5分钟 作者 | 第一财经 吴斯旻 "十五五"规划纲要明确提出实施健康优先发展战略，并将生物制药列为新兴支柱产业，为跨国医药企 业参与"健康中国"建设提供了新机遇。 近日，"中国发展高层论坛2026年年会"（下称"年会"）召开。年会期间，国家卫健委和中央财经委等 有关部门均释放了深化医药卫生体制改革、促进医疗等重点领域科技创新、优化营商环境和加大对外 开放的积极信号。 多名与会跨国医药企业高管均积极回应，将扩大在华业务，加大在细胞疗法等前沿领域的本地化生产 能力，继续投资本地创新并加强创新合作。 在深度参与中国医药创新的过程中，这些跨国医药企业对中国医药创新生态也有更多期待：其一，优 化完善与创新相匹配的知识产权保护体系、价值认定和支付机制，为企业提供制度性激励；其二，以 临床需求为导向，推动市场和监管的关注点从产品创新转向系统性集成创新，加大中国在疾病治理和 创新方案上的输出能力，完善涵盖患者、医疗机构、国内外制药企业和科研院所、社会资本以及监管 部门等多方的医药创新生态。 跨国药企深化在华布局 据国家卫健委消息，22日，上述年会"谋划'十五五'国民健 ...

More than 80 global executives gathered in Beijing for the China Development Forum, signaling renewed corporate interest in the Chinese market despite ongoing geopolitical tensions. The discussions reflected a cautious but clear pivot toward expansion, as Beijing continues to gradually ease restrictions on foreign businesses.Eli Lilly Expands China Bet With Obesity Drug FocusIn March, Eli Lilly outlined an aggressive long-term strategy for China, announcing plans to invest $3 billion in the country over the ...